Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Fixed-Duration Bispecific Antibodies Are Effective, Safe, and Convenient for Follicular Lymphoma

May 29th 2025

Vivek Patel, MD, discusses the safety of bispecific antibodies and the choice between these agents and CAR T-cell therapy for follicular lymphoma.

Fifteen-Year Follow-Up Data Confirm Rituximab Delays the Need for New Treatment in Advanced Follicular Lymphoma

May 29th 2025

Rituximab monotherapy delayed the time to next treatment vs watchful waiting in advanced stage, asymptomatic, low tumor burden follicular lymphoma.

NCCN Guidelines Now Recommend Pemivibart for COVID-19 Prevention in B-Cell Lymphomas

May 28th 2025

Updated NCCN Guidelines recommend pemivibart in immunocompromised patients with B-cell lymphomas who are at higher risk of contracting COVID-19.

Bispecific Antibodies Gain Ground in Frontline Follicular Lymphoma Management

May 27th 2025

Vivek Patel, MD, discusses the evolving roles of chemoimmunotherapy and bispecific antibodies in the first-line follicular lymphoma setting.

The OncFive: Top Oncology Articles for the Week of 5/18

May 24th 2025

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

Dr Patel on Ongoing Research With Subcutaneous Bispecific Antibodies in Frontline Follicular Lymphoma

May 23rd 2025

Vivek G. Patel, MD, discusses the potential advantages of subcutaneous bispecific antibodies that are being evaluated in frontline follicular lymphoma.

Dr Ip on the Limitations of Real-World CAR T-Cell Therapy Research in LBCL

May 23rd 2025

Andrew Ip, MD, discusses how the limitations of real-world studies reveal gaps in LBCL research that future CAR T-cell therapy clinical trials may address.

CHMP Recommends EU Approval of Obe-Cel for Relapsed/Refractory B-ALL

May 23rd 2025

The EMA’s CHMP has recommended the approval of obecabtagene autoleucel for adult patients with relapsed/refractory B-ALL.

Updated STARGLO Data Show Maintained OS Benefit With Glofitamab Plus Chemo in R/R DLBCL

May 23rd 2025

Two-year follow-up data continued to show an overall survival benefit with glofitamab plus chemotherapy in relapsed/refractory DLBCL.

Artificial Intelligence Proves Its Worth in Cancer Treatment, Drug Development, and Other Real-World Applications

May 22nd 2025

Multiple experts on artificial intelligence in cancer care discuss its ever-expanding role in several areas of oncology.

Treatment Trends and Ongoing Research in Pediatric Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss ongoing research in pediatric acute leukemia.

Factors to Consider in Pediatric Acute Leukemia Management

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss key factors for the management of pediatric acute leukemia.

Breaking Down Treatment Expectations With Revumenib in Pediatric KMT2A+ R/R Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss treatment expectations with revumenib in pediatric relapsed/refractory acute leukemia.

Integrating 25-mg Tablets of Revumenib Into Pediatric R/R Acute Leukemia Management

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the use of 25-mg tablets of revumenib in pediatric KMT2A-translocated relapsed/refractory acute leukemia.

When to Test for KMT2A Rearrangements and Other Alterations in Pediatric Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss the optimal timing of testing for KMT2A rearrangements in pediatric acute leukemia.

Implications of the FDA Approval of Revumenib in KMT2A+ R/R Acute Leukemia

May 22nd 2025

Lia Gore, MD, and Sarah K. Tasian, MD, on the significance of the FDA approval of revumenib in KMT2A-rearranged relapsed/refractory acute leukemia.

Current Treatment Strategies in Pediatric R/R AML and ALL

May 21st 2025

Lia Gore, MD, and Sarah K. Tasian, MD, discuss current treatment trends in pediatric relapsed/refractory acute leukemia.

Pola-R-CHP Is Associated With Improved 2-Year PFS Rates in Older Untreated DLBCL Population

May 21st 2025

Pola-R-CHP demonstrated clinically meaningful PFS and safety in older patients with previously untreated diffuse large B-cell lymphoma.

China’s NMPA Approves Tafasitamab Plus Lenalidomide in Transplant-Ineligible R/R DLBCL

May 21st 2025

Tafasitamab plus lenalidomide has received NMPA approval for patients with relapsed/refractory DLBCL who are ineligible for ASCT.

Dr Falchi on the Safety of Fixed-Duration Epcoritamab Plus Lenalidomide/Rituximab in R/R Follicular Lymphoma

May 20th 2025

Lorenzo Falchi, MD, discusses the safety and pharmacodynamics of fixed-duration epcoritamab plus lenalidomide and rituximab in relapsed/refractory follicular lymphoma